Rational Pharmacotherapy in Cardiology

Advanced search

Lipid profile of patients with arterial hypertension who underwent COVID-19: possibilities of drug therapy/ LEADER


Aim. To study the dynamics of the lipid profile of hypertensive patients with dyslipidemia who underwent COVID-19.

Material and methods. Hypertensive patients with dyslipidemia who underwent COVID-19 [n=126; 58 men and 68 women; median age 60 (56.0; 65.5) years] examined. Patients were included into two groups: group 1 (n=64) received a single pill combination of lisinopril + amlodipine + rosuvastatin; 2 groups (n=62) continued the previous drug treatment. Clinical, demographic, office blood pressure (BP), total cholesterol (TC), low density lipoprotein cholesterol (LDL-c), high density lipoprotein cholesterol, triglycerides, C-reactive protein (CRP) levels were assessed in all patients in 3 visits within 24 weeks.

Results. The groups did not differ in prior antihypertensive therapy (except for more frequent use of angiotensin II receptor blockers in group 2, p<0.05), lipid profile and blood pressure parameters at study entry. A decrease in systolic (by 9.5%) and diastolic blood pressure (by 12.1%) after 24 weeks was found in group 1 compared with 4.29% and 5.56%, respectively, in group 2 (p<0.05). A decrease in the level of total cholesterol by 14.5% and LDL-c by 31.4% after 24 weeks was found in group 1 compared with 11.2% and 9.7%, respectively, in group 2 (p<0.05). The level of CRP during the observation period decreased by 53.7% in group 1 versus 43.4% in patients of group 2 (p<0.05).

Conclusion. The single pill combination of lisinopril/amlodipine/rosuvastatin in hypertensive patients with dyslipidemia who underwent COVID-19 led to an improvement in lipid profile and blood pressure control.

About the Authors

I. A. Zolotovskaya
Samara State Medical University
Russian Federation

Irina A. Zolotovskaya

V. P. Kuzmin
Samara State Medical University
Russian Federation

Vladimir P. Kuzmin

O. A. Rubanenko
Samara State Medical University
Russian Federation

Olesya A. Rubanenko

P. R. Shatskaya
Samara State Medical University
Russian Federation

Polina R. Shatskaya

A. S. Salasyuk
Volgograd State Medical University
Russian Federation

Alla S. Salasyuk


1. Metelskaya VA, Shalnova SA, Deev AD, et al. Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of the ESSE-RF Study). Preventive Medicine. 2016;19(1):1523 (In Russ.) DOI:10.17116/profmed201619115-23.

2. Xu S, Yang H, Wang J, et al. Clinical Characteristics Among Hypertension Patients with Dislipidemia In Shanghai, China. Value Health. 2014;17(7):A720. DOI:10.1016/j.jval.2014.08.013

3. Yusuf S, Lonn E, Pais P, et al. Blood pressure and cholesterol lowering in persons without cardiovascular disease. New Engl J Med. 2016;374(21):2032-43. DOI:10.1056/NEJMoa1600177

4. Schiffrin EL, Flack JM, Ito S, et al. Hypertension and COVID-19. Am J Hypertens. 2020;33(5):373-4. DOI:10.1093/ajh/hpaa057

5. Zhou F, Yu T, Du R, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. DOI:10.1016/S0140-6736(20)30183-5.

6. Tadic M, Cuspidi C, Grassi G, Mancia G. COVID-19 and arterial hypertension: Hypothesis or evidence? J Clin Hypertens (Greenwich). 2020;22(7):1120-6. DOI:10.1111/jch.13925.

7. Drapkina OM, Lishuta AS. Using a combination of perindopril, indapamide and rosuvastatin in the treatment of patients with hypertension and dyslipidemia. Rational Pharmacotherapy in Cardiology. 2017;13(4):454-62 (In Russ.) DOI:10.20996/1819-6446-2017-13-4-454-462.

8. Konradi AO, Alieva AS. Hypertension and dyslipidemia. Parallel risk factor control: role of fixed combination. Arterial Hypertension. 2021;27(3):376-83 (In Russ.) DOI:10.18705/1607-419X2021-27-3-376-383.

9. Kukharchuk V V, Ezhov M V, Sergienko I V, et al. Diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations, VII revision. Journal of Atherosclerosis and Dyslipidemias. 2020;(1):7-42 (In Russ.) DOI:10.34687/2219-8202.JAD.2020.01.0002.

10. Soška V. Early and concurrent therapy of dyslipidemia and hypertension: when to start it and how to maintain patient´s good and long-term adherence? Vnitr Lek. 2021;67(1):37-40.

11. Arutyunov GP, Tarlovskaya EI, Arutyunov AG, et al. Registry "Analysis of the dynamics of comorbid diseases in patients after SARS-COV-2 infection" (ACTIV). Evaluation of the influence of combinations of initial comorbidities in patients with COVID-19 on the prognosis. Ter Arkhiv. 2022;94(1):32-47 (In Russ.)

12. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. DOI:10.1001/jama.2020.1585.

13. Nedogoda S.V. Cardiovascular pathology and COVID-19: briefly about the main thing. Consilium Medicum. 2020;22(5):19-21 (In Russ.)

14. Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Me-ta-Analysis. Arch Acad Emerg Med. 2020 M;8(1):e35.

15. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. DOI:10.1016/S0140-6736(20)30566-3.

16. Nedogoda SV, Chumachek EV, Ledyaeva AA, et al. Optimal organoprotection, control of blood pressure and metabolic disorder with the fixed combination of lisinopril, amlodipine and rosuvastatin in systemic hypertension. Russian Journal of Cardiology. 2018;(4):49-55 (In Russ.) DOI:10.15829/1560-4071-2018-4-49-55.

17. A fixed-dose lisinopril+amlodipine+rosuvastatin combination: prospects for its use in patients with hypertension and concomitant dyslipidemia]. Ter Arkhiv. 2017;89(12):133-40 (In Russ.) DOI:10.17116/terarkh20178912133-140.

18. Nedogoda SV, Chumachek EV, Ledyaeva AA, et al. Improvement in blood pressure control, organ protection and correction of metabolic disorders in patients with arterial hypertension when switching from dual combinations, including a diuretic, to a combination of lisinopril + amlodipine + rosuvastatin. Systemic Hypertension. 2018;15(2):24-31 (In Russ.) DOI:10.26442/2075-082X_2018.2.2431

19. Semenova АЕ, Sergienko IV. Lisinopril, Amlodipine, Rosuvastatin as a Novel Fixed Combination in the Fight Against Cardiovascular Disease. Kardiologiia. 2017;57(10):73-9 (In Russ.) DOI:10.18087/cardio.2017.10.10044.

20. Blankova ZN, Aslanian NS, Smolianinova NG, Ageev FT. Treatment of patients with high cardiovascular risk: a modern view on combined therapy. Systemic Hypertension. 2017;14(1):12-6 (In Russ.)

21. Nedogoda S.V., Sabanov A.V., Bychkova O.I. Barriers to effective outpatient hypertension treatment: a view of physicians and patients. Russian Journal of Cardiology. 2020;25(4):3776 (In Russ.) DOI:10.15829/1560-4071-2020-3776.

22. Konyi A, Sarszegi Z, Hild G, Gaszner B. Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high- /very high-risk patients. J Comp Eff Res. 2016;5(4):355-64. DOI:10.2217/cer-2016-0003.

23. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Goup. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med. 2008;359(21):2195207 DOI:10.1056/NEJMoa0807646.

24. Karpov YA. Study TRIUMVIRATE: Reducing the Risk of Cardiovascular Events in Hypertensive Patients Using Triple Combination Antihypertensive and Lipid-Lowering Drugs. Kardiologiia. 2015;55(9):105 (In Russ.) DOI: 10.18565/cardio.2015.9.10-15.

25. Liu HH, Cao YX, Sun D, et al. High-sensitivity C-reactive protein and hypertension: combined effects on coronary severity and cardiovascular outcomes. Hypertens Res. 2019;42(11):1783-93. DOI:10.1038/s41440-019-0293-8.

26. Bisaria S, Terrigno V, Hunter K, Roy S. Association of Elevated Levels of Inflammatory Marker HighSensitivity C-Reactive Protein and Hypertension. J Prim Care Community Health. 2020;11:2150132720984426. DOI:10.1177/2150132720984426.

27. Wang Z, Yang B, Li Q, et al. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020;71(15):769-77.

28. Nemcsik J, Cseprekál O, Tislér A. Measurement of arterial stiffness: A novel tool of risk stratification in hypertension. Adv Exp Med Biol. 2017;956:475-88. DOI:10.1007/5584_2016_78.


For citations:

Zolotovskaya I.A., Kuzmin V.P., Rubanenko O.A., Shatskaya P.R., Salasyuk A.S. Lipid profile of patients with arterial hypertension who underwent COVID-19: possibilities of drug therapy/ LEADER. Rational Pharmacotherapy in Cardiology. 2022;18(3):282-288. (In Russ.)

Views: 1754

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)